Dashboard
Manage Tickers

PEPGPepGen Inc.

Nasdaq pepgen.com


$ 13.60 $ -0.17 (-1.23 %)    

Thursday, 16-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.64 $ -0.92 (-0.2 %)
DIA $ 399.14 $ -0.07 (-0.02 %)
SPY $ 528.49 $ -1.09 (-0.21 %)
TLT $ 92.06 $ -0.09 (-0.1 %)
GLD $ 220.06 $ -0.86 (-0.39 %)
$ 13.65
$ 13.37
$ 0.00 x 0
$ 0.00 x 0
$ 13.37 - $ 13.69
$ 3.72 - $ 17.51
21,483
na
391.16M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-06-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 06-16-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-pepgen-maintains-26-price-target
HC Wainwright & Co. Reiterates Buy on PepG...
05/15/2024 15:16:58

HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.

wedbush-reiterates-outperform-on-pepgen-maintains-20-price-target
Wedbush Reiterates Outperform on PepGen, M...
05/15/2024 13:45:25

Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.

correction-pepgen-q1-2024-gaap-eps-063-beats-074-estimate
CORRECTION: PepGen Q1 2024 GAAP EPS $(0.63...
05/14/2024 20:36:01

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 14....

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/12/2024 12:09:54

insiders-buying-gamestop-and-2-other-stocks
Insiders Buying GameStop And 2 Other Stocks
04/10/2024 12:11:19

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

pepgen-receives-us-fda-orphan-drug-and-rare-pediatric-disease-designations-for-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy
PepGen Receives U.S. FDA Orphan Drug And R...
03/13/2024 11:01:33

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/07/2024 17:31:22

pepgen-reported-march-6-q4-2023-gaap-eps-0810-beats-1010-estimate
PepGen Reported March 6 Q4 2023 GAAP EPS $...
03/07/2024 15:55:58

PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.810) per share which beat the analyst consensus estimate of $(1.010) by 1...

wedbush-maintains-outperform-on-pepgen-lowers-price-target-to-20
Wedbush Maintains Outperform on PepGen, Lo...
03/07/2024 13:14:09

Wedbush analyst Laura Chico maintains PepGen (NASDAQ:PEPG) with a Outperform and lowers the price target from $21 to $20.

pepgen-announces-clearance-of-cta-by-uk-medicines--healthcare-products-regulatory-agency-to-begin-connect2-edo51-a-phase-2-clinical-trial-designed-to-support-potential-accelerated-approval-of-pgn-edo51-for-the-treatment-of-duchenne-muscular-dystrophy
PepGen Announces Clearance of CTA by UK Me...
03/04/2024 12:04:59

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies wi...

pepgen-receives-fda-fast-track-designation-for-pgn-edodm1-for-myotonic-dystrophy-type-1
PepGen Receives FDA Fast Track Designation...
02/20/2024 13:03:26

over-37m-bet-on-this-industrial-stock-check-out-these-4-stocks-insiders-are-buying
Over $37M Bet On This Industrial Stock? Ch...
02/14/2024 13:28:21

Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades.

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
02/07/2024 17:31:16

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
02/07/2024 13:06:01

pepgen-reports-pricing-of-offering-of-753m-shares-of-its-common-stock-at-10635-per-share
PepGen Reports Pricing Of Offering Of 7.53...
02/07/2024 12:39:02

The aggregate gross proceeds to PepGen from this offering are expected to be approximately $80.1 million, before deducting unde...

top-4-health-care-stocks-that-may-crash-this-quarter
Top 4 Health Care Stocks That May Crash Th...
02/02/2024 13:21:44

As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
01/30/2024 17:31:12

wedbush-reiterates-outperform-on-pepgen-maintains-21-price-target
Wedbush Reiterates Outperform on PepGen, M...
01/30/2024 16:00:11

Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $21 price target.

pepgen-announced-first-patient-dosed-in-connect1-edo51-phase-2-clinical-trial-of-pgn-edo51-for-duchenne-muscular-dystrophy-patients-amenable-to-exon-51-skipping
PepGen Announced First Patient Dosed in CO...
01/08/2024 12:20:16

PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies wi...

pepgen-announces-first-patient-dosed-in-phase-1-freedom-dm1-clinical-trial-of-pgn-edodm1-for-myotonic-dystrophy-type-1
PepGen Announces First Patient Dosed In Ph...
12/18/2023 13:03:55

- Safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg PGN-EDODM1 dose level in patients from F...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION